Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET OVEREXPRESSION ( ENST00000318493.11 )
MET OVEREXPRESSION ( ENST00000318493.11 )
Associated Disease
stomach carcinoma
Source Database
CIViC Evidence
Description
In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarcinoma were randomized to chemotherapy (epirubicin, cisplatin, capecitabine) with placebo or MET inhibitor rilotumumab. Study treatment was stopped early because of a higher number of deaths in the rilotumumab arm. Median overall survival was 8·8 months (95% CI 7·7-10·2) in the rilotumumab group compared with 10·7 months (9·6-12·4) in the placebo group (stratified hazard ratio 1·34, 95% CI 1·10-1·63; p=0·003).
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/5835
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/621
Rating
5
Evidence Type
Predictive
Disease
Stomach Carcinoma
Evidence Direction
Does Not Support
Drug
Rilotumumab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
28958504
Drugs
Drug NameSensitivitySupported
RilotumumabSensitivityfalse